Tacrine is implicated in oxidative stress in the laboratory guinea pig model

Neuroendocrinology Letters

Volumn 33, Issue SUPPL. 3, 2012, Pages 136-144

  Kracmarova, Alzbeta ^a   Bandouchova, Hana ^b   Pikula, Jiri ^b   Pohanka, Miroslav ^a  

^a UNIVERSITY OF DEFENCE   (Czech Republic)

^b UNIVERSITY OF VETERINARY AND PHARMACEUTICAL SCIENCES   (Czech Republic)

Author keywords

Acetylcholinesterase; Alzheimer disease; Antioxidant; Neurodegeneration; Oxidative stress; Tacrine

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CASPASE 3; CREATININE; GLUCOSE; GLUTATHIONE REDUCTASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LACTATE DEHYDROGENASE; SUPEROXIDE DISMUTASE; TACRINE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRIACYLGLYCEROL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EUTHANASIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BRAIN TISSUE; CEREBELLUM; CHEMICAL ANALYSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE MODEL; DOSE RESPONSE; ENZYME ACTIVITY; EXPERIMENTAL GUINEA PIG; FEMALE; FRONTAL LOBE; GLUCOSE BRAIN LEVEL; HEART; KIDNEY; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER; NONHUMAN; OCCIPITAL LOBE; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; SPLEEN; TEMPORAL LOBE; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL;

EID: 84874808443     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Benzie IFF, Strain JJ (1996). The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": The FRAP assay. Anal Biochem. 239: 70-76.
2. Blank K, Cheong JA, Cohen GD, GAitz C, Gottlieb G, Katz IR, Leuchter A, Maletta G, Margolin R, Sakauye K, Shamoian C (1994). Impact of tacrine in the care of patients with Alzeimers-disease - what we know one-year after FDA approval. Am J Geriatr Psych. 2: 285-289. (Pubitemid 24338778)
3. Cao G, Cutler RG (1995). Protein oxidation and aging. Arch Biochem Biophys. 320: 106-114.
4. Crismon ML (1994). Tacrine - 1st drug approved for Alzheimers-disease. Annals Pharmacother. 28: 744-751.
5. Davis KL, Thal LJ, Gamzu ER, Davis CS, Woolson RF, Gracon SI, et al. (1992). A double-blind placebo-controlled multicenter study of tacrine for Alzheimer's disease. N Engl J Med. 327: 1253-1259.
6. Finaud J, Lac G, Filaire E (2006). Oxidative stress: relationship with exercise and training. Sports Med. 36: 327-358.
7. Goh CW, Aw CC, Lee JH, Chen CP, Browne ER (2011). Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young lister hooded rats. Drug Metab Dispos. 39: 402-411.
8. Greggio S, Rosa RM, Dolganov A, de Oliveira IM, Menegat FD, Henriques JAP, et al (2009). NAP prevents hippocampal oxidative damage in neonatal rats subjected to hypoxia-induced seizures. Neurobiol Dis. 36: 435-444.
9. Hartl D, Schuldt V, Forler S, Zabel C, Klose J, Rohe M (2012). Presymptomatic Alterations in Energy Metabolism and Oxidative Stress in the APP23 Mouse Model of Alzheimer Disease. J Proteome Res. DOI: 10.1021/pr300021e
10. Kaplan B, Cetin F, Elbeg S (2010). The effects of vitamin C administration, acute food deprivation, and acute food intake on vitamin C levels in different brain areas of guinea pigs. Int J Vitam Nutr Res. 80: 197-204.
11. Kobayashi Y, Yoshimitsu T, Usui T (1983). Evaluation of lipid peroxidation of human erythrocyte hemolysates. J Immunol Methods. 64: 17-23. (Pubitemid 14241088)
12. Kohen R, Oron M, Zelkowicz A, Kanevsky E, Farfouri S, Wormser U (2004). Low molecular weight antioxidants released from the skin's epidermal layers: an age dependent phenomenon in the rat. Exp Gerontol. 39: 67-72. (Pubitemid 38068261)
13. Korolainen MA, Nyman TA, Nyyssonen P, Hartikainen ES, Pirttila T (2007). Multiplexed proteomic analysis of oxidation and concentrations of cerebrospinal fluid proteins in Alzheimer disease. Clin Chem. 53: 657-665. (Pubitemid 46580235)
14. Little JT, Walsh S, Aisen PS (2008). An update on huperzine A as a treatment for Alzheimer's disease. Expert Opin Investig Drugs. 17: 209-215. (Pubitemid 351578201)
15. Lou GL, Montgomery, Sitar DS (1996). Bioavailability and pharmacokinetic disposition of tacrine in elderly patients with Alzheimer's disease. J Phychiatr Neurosci. 21: 334-339.
16. Luppi B, Bigucci F, Corace G, Delucca A, Cerchiara T, Sorrenti M, et al (2011). Albumin nanoparticles carrying cyclodextrins for nasal delivery of the anti-Alzheimer drug tacrine. Eur J Pharm Sci. 44: 559-565.
17. Madden S, Spaldin V, Park BK (1995). Clinical pharmacokinetics of tacrine. Clin Pharmacokinet. 28: 449-457.
18. Marques LA, Kool J, de Kanter F, Lingeman H, Niessen W, Irth H (2010). Production and on-line acetylcholinesterase bioactivity profiling of chemical and biological degradation products of tacrine. J Pharm Biomed Anal. 53: 609-616.
19. Meng Q, Ru J, Zhang G, Shen C, Schmitmeier S, Bader A (2007). Re-evaluation of tacrine hepatotoxicity using gel entrapped hepatocytes. Toxicol Lett. 168: 140-147. (Pubitemid 46054364)
20. Necas J, Bartosiková L, Benes L, Janostikova E, Bartosik T, Klusakova J, et al(2005). Influence of antioxidant effect of stobadine derivative in condition of kidney ischemia-reperfusion in a preclinical experiment (effect in prophylaxis). Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 49: 385-388.
21. Osseni RA, Debbasch C, Christen MO, Rat P, Warnet JM (1999). Tacrine-induced Reactive Oxygen Species in a Human Liver Cell Line: The Role of Anethole Dithiolethione as a Scavenger. Toxicol In Vitro. 13: 683-688. (Pubitemid 29354196)
22. Pohanka M, Bandouchova H, Sobotka J, Sedlackova J, Soukupova I, Pikula J (2009). Ferric reducing antioxidant power and square wave voltammetry for assay of low molecular weight antioxidants in blood plasma: Performance and comparison of methods. Sensors. 9: 9094-9103.
23. Pohanka M, Pejchal J, Horackova S, Kuca K, Bandouchova H, Damkova V, Pikula J (2010a). Modulation of ionizing radiation generated oxidative stress by HI-6 (asoxime) in a laboratory rat model. Neuro Endocrinol Lett. 31: 62-68.
24. Pohanka M, Sobotka J, Jilkova M, Stetina R (2010b). Oxidative stress after sulfur mustard intoxication and its reduction by melatonin: efficacy of antioxidant therapy during serious intoxication. Drug Chem Toxicol. 34: 85-91.
25. Pohanka M (2011) Cholinesterases, a target of pharmacology and toxicology. Biomed Pap Olomouc 155: 219-223.
26. Pohanka M, Hrabinova M, Zemek F, Drtinova L, Bandouchova H, Pikula J (2011a). Huperzine induces alteration in oxidative balance and antioxidants in a guinea pig model. Neuro Endcrinol Lett. 32: 95-100.
27. Pohanka M, Sobotka J, Stetina R (2011a). Sulfur mustard induced oxidative stress and its alteration by epigallocatechin gallate. Toxicol Lett. 201: 105-109.
28. Pohanka M (2012) Acetylcholinesterase inhibitors; a patent review (2008-present). Expert Opin Ther Pat. 22: 871-886.
29. Pool WF, Reily MD, Bjorge SM, Woolf TF (1997). Metabolic disposition of the cognition activator tacrine in rats, dogs, and humans - species comparisons. Drug Met Disp. 25: 590-597. (Pubitemid 27213100)
30. Qian S, Wo SK, Zuo Z (2012). Pharmacokinetics and brain dispositions of tacrine and its major bioactive monohydroxylated metabolites in rats. J Pharm Biomed Anal. 61: 57-63.
31. Salgo MG, Pryor WA (1996). Trolox inhibits peroxynitrite-mediated oxidative stress and apoptosis in rat thymocytes. Arch Biochem Biophys. 333: 482-488. (Pubitemid 26304917)
32. Saxena G, Singh SP, Agrawal R, Nath C (2008). Effect of donepezil and tacrine on oxidative stress in intracerebral streptozotocin-induced model of dementia in mice. Eur J Pharm Sci. 581: 283-289.
33. Schroeter H, Spencer JPE, Rice-Evans C, Williams RJ (2001). Flavonoids protect neurons from oxidized low-density-lipoprotein-induced apoptosis involving c-Jun N-terminal kinase (JNK), c-Jun and caspase-3. Biochem J. 358: 547-557. (Pubitemid 32896942)
34. Shi Q, Gibson GE (2007). Oxidative stress and transcriptional regulation in Alzheimer's disease. Alzheimer Dis Assoc Disord. 21: 276-291. (Pubitemid 350307432)
35. Wagstaff AJ, McTavish D (1994). Tacrine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer's disease. Drugs Aging. 4: 510-540. (Pubitemid 2093496)
36. Xiao XQ, Wang R, Tang XC (2000). Huperzine A and tacrine attenuate beta-amyloid peptide-induced oxidative injury. J Neurosci Res. 61: 564-569.